Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Other Working Capital Changes (2016 - 2025)

KalVista Pharmaceuticals' Other Working Capital Changes history spans 10 years, with the latest figure at $1.3 million for Q2 2025.

  • For Q2 2025, Other Working Capital Changes fell 11.29% year-over-year to $1.3 million; the TTM value through Apr 2025 reached $1.4 million, up 160.97%, while the annual FY2025 figure was $1.4 million, 152.42% up from the prior year.
  • Other Working Capital Changes for Q2 2025 was $1.3 million at KalVista Pharmaceuticals, up from -$2.1 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $1.4 million in Q2 2024 and bottomed at -$2.1 million in Q4 2024.
  • The 3-year median for Other Working Capital Changes is $783000.0 (2024), against an average of $71142.9.
  • The largest annual shift saw Other Working Capital Changes fell 21.93% in 2024 before it decreased 11.29% in 2025.
  • A 3-year view of Other Working Capital Changes shows it stood at -$1.8 million in 2023, then decreased by 19.27% to -$2.1 million in 2024, then soared by 160.88% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for KALV's Other Working Capital Changes are $1.3 million (Q2 2025), -$2.1 million (Q4 2024), and $783000.0 (Q3 2024).